NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $145.31
  • Forecasted Upside: 7.78 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$134.82
▼ -3.89 (-2.80%)
1 month | 3 months | 12 months
Get New Exact Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$145.31
▲ +7.78% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $145.31, with a high forecast of $226.00 and a low forecast of $70.00. The average price target represents a 7.78% upside from the last price of $134.82.
Buy
The current consensus among 15 investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2019
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/26/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2021Robert W. BairdLower Price TargetOutperform$169.00 ➝ $163.00Low
i
2/17/2021Stifel NicolausBoost Price TargetBuy$150.00 ➝ $165.00Low
i
2/17/2021SVB LeerinkBoost Price TargetMarket Perform ➝ Outperform$170.00 ➝ $180.00Low
i
Rating by P. Souda at SVB Leerink LLC
2/17/2021CowenBoost Price TargetOutperform$154.00 ➝ $180.00Low
i
1/27/2021TruistInitiated CoverageBuy$226.00 ➝ $226.00Medium
i
1/21/2021SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $170.00Medium
i
Rating by P. Souda at SVB Leerink LLC
1/12/2021Canaccord GenuityBoost Price TargetBuy$160.00 ➝ $165.00Low
i
10/29/2020UBS GroupDowngradeBuy ➝ Neutral$125.00 ➝ $140.00High
i
10/28/2020Canaccord GenuityBoost Price TargetBuy$120.00 ➝ $145.00Low
i
10/28/2020OppenheimerBoost Price Target$115.00 ➝ $150.00Low
i
10/28/2020BTIG ResearchBoost Price Target$140.00 ➝ $155.00Low
i
10/28/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $140.00Low
i
10/28/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$135.00 ➝ $150.00Low
i
10/28/2020SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $160.00Low
i
10/28/2020BenchmarkBoost Price TargetBuy$110.00 ➝ $145.00Low
i
10/28/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$120.00 ➝ $140.00Medium
i
9/25/2020Canaccord GenuityBoost Price TargetBuy$115.00 ➝ $120.00Low
i
7/31/2020SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $115.00High
i
7/31/2020BenchmarkBoost Price TargetBuy$90.00 ➝ $110.00Low
i
7/31/2020CitigroupBoost Price TargetBuy$110.00 ➝ $120.00Low
i
7/8/2020OppenheimerReiterated RatingBuyHigh
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
6/25/2020CitigroupBoost Price TargetBuy$100.00 ➝ $110.00Medium
i
5/7/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $92.00Low
i
Rating by Catherine Ramsey Schulte at Robert W. Baird
5/7/2020Bank of AmericaBoost Price TargetBuy$88.00 ➝ $94.00Low
i
5/7/2020Craig HallumLower Price TargetIn-Line ➝ Buy$99.00 ➝ $92.00Low
i
5/7/2020Canaccord GenuityLower Price TargetBuy$120.00 ➝ $110.00High
i
Rating by Max Masucci at Canaccord Genuity
5/7/2020SVB LeerinkLower Price TargetOutperform$100.00 ➝ $90.00High
i
4/28/2020UBS GroupLower Price TargetBuy$135.00 ➝ $115.00High
i
4/22/2020CitigroupLower Price TargetBuy$120.00 ➝ $100.00Medium
i
4/22/2020Robert W. BairdLower Price TargetOutperform$100.00 ➝ $90.00High
i
Rating by Catherine Ramsey Schulte at Robert W. Baird
4/21/2020OppenheimerReiterated RatingBuy$115.00Low
i
4/17/2020Craig HallumLower Price TargetBuy$127.00 ➝ $99.00High
i
4/2/2020Stifel NicolausLower Price TargetBuy$110.00 ➝ $90.00Low
i
Rating by Daniel Arias at Stifel Nicolaus
4/2/2020Evercore ISIInitiated CoverageOutperform$70.00High
i
2/14/2020Stifel NicolausReiterated RatingBuy$110.00N/A
i
Rating by Daniel Arias at Stifel Nicolaus
2/12/2020Robert W. BairdReiterated RatingBuyLow
i
Rating by Catherine Ramsey Schulte at Robert W. Baird
2/12/2020Canaccord GenuityReiterated RatingBuy$120.00High
i
Rating by Max Masucci at Canaccord Genuity
2/6/2020Canaccord GenuityReiterated RatingBuy$120.00Low
i
Rating by Max Masucci at Canaccord Genuity
1/10/2020BTIG ResearchInitiated CoverageBuy$127.00High
i
Rating by Amanda Murphy at BTIG Research
1/6/2020CitigroupInitiated CoverageBuy$120.00Low
i
12/13/2019Dougherty & CoInitiated CoverageBuy$120.00Low
i
Rating by K. Bauser at Dougherty & Co
11/14/2019Stifel NicolausInitiated CoverageBuy$110.00High
i
10/31/2019Bank of AmericaReiterated RatingBuy$135.00Medium
i
10/30/2019SVB LeerinkLower Price TargetOutperform$133.00 ➝ $105.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
10/30/2019Canaccord GenuityLower Price TargetBuy$135.00 ➝ $120.00High
i
Rating by Mark Massaro at Canaccord Genuity
10/30/2019Jefferies Financial GroupLower Price TargetBuy$138.00 ➝ $120.00High
i
10/17/2019Bank of AmericaBoost Price TargetBuy$130.00 ➝ $135.00Low
i
9/26/2019OppenheimerInitiated CoverageOutperform$130.00Medium
i
9/24/2019SVB LeerinkReiterated RatingBuyHigh
i
Rating by Puneet Souda at SVB Leerink LLC
9/23/2019BenchmarkUpgradeHold ➝ Buy$130.00High
i
9/10/2019William BlairReiterated RatingBuyLow
i
Rating by Brian Weinstein at William Blair
9/10/2019Canaccord GenuityReiterated RatingBuy$135.00Low
i
8/1/2019UBS GroupBoost Price TargetBuy$120.00 ➝ $143.00Low
i
Rating by Daniel Brennan at UBS Group AG
7/30/2019Craig HallumBoost Price TargetBuy$115.00 ➝ $127.00Medium
i
Rating by Per Ostlund at Craig Hallum
7/29/2019CowenBoost Price TargetOutperform$125.00 ➝ $135.00Low
i
7/17/2019Canaccord GenuityReiterated RatingBuy$118.00 ➝ $125.00Low
i
5/1/2019Jefferies Financial GroupBoost Price TargetBuy$100.00 ➝ $115.00Low
i
5/1/2019UBS GroupBoost Price TargetBuy ➝ Buy$115.00 ➝ $120.00Low
i
Rating by Daniel Brennan at UBS Group AG
5/1/2019Craig HallumReiterated RatingBuy$95.00 ➝ $115.00Low
i
Rating by Per Ostlund at Craig Hallum
5/1/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$100.00 ➝ $110.00Medium
i
5/1/2019BTIG ResearchBoost Price TargetBuy$130.00Low
i
4/16/2019UBS GroupBoost Price TargetBuy ➝ Buy$109.00 ➝ $115.00Low
i
Rating by Daniel Brennan at UBS Group AG
2/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$85.00 ➝ $120.00Medium
i
2/22/2019UBS GroupSet Price TargetBuy$109.00Low
i
Rating by Daniel Brennan at UBS Group AG
2/22/2019Craig HallumSet Price TargetIn-Line ➝ Buy$77.00 ➝ $95.00High
i
2/22/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$110.00High
i
2/21/2019Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $102.00High
i
1/28/2019UBS GroupBoost Price TargetBuy$100.00 ➝ $109.00Medium
i
Rating by Daniel Brennan at UBS Group AG
1/14/2019Canaccord GenuityBoost Price TargetBuy$87.00 ➝ $95.00High
i
1/7/2019William BlairReiterated RatingOutperformHigh
i
11/29/2018UBS GroupSet Price TargetBuy$100.00Low
i
Rating by Daniel Brennan at UBS Group AG
10/31/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$74.00 ➝ $84.00Low
i
10/30/2018UBS GroupSet Price TargetBuy$100.00High
i
Rating by Daniel Brennan at UBS Group AG
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$100.00Low
i
9/12/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$72.00 ➝ $87.00Low
i
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $85.00Low
i
9/6/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$68.00 ➝ $92.00Medium
i
Rating by Derik De Bruin at Bank of America Co.
9/5/2018CowenBoost Price TargetOutperform$65.00 ➝ $100.00High
i
9/5/2018BenchmarkReiterated RatingHold ➝ HoldHigh
i
8/30/2018The Goldman Sachs GroupBoost Price TargetNeutral$75.00Low
i
8/23/2018Craig HallumBoost Price TargetBuy$54.00 ➝ $74.00Medium
i
8/23/2018Jefferies Financial GroupReiterated RatingBuy$74.00High
i
8/23/2018SVB LeerinkReiterated RatingOutperform$90.00High
i
Rating by Puneet Souda at SVB Leerink LLC
8/23/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $74.00High
i
8/22/2018BTIG ResearchBoost Price TargetBuy$95.00High
i
8/13/2018Canaccord GenuityReiterated RatingBuy$62.00 ➝ $65.00Low
i
8/3/2018Canaccord GenuityReiterated RatingBuy$62.00Medium
i
8/2/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$60.00 ➝ $57.00High
i
8/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$75.00 ➝ $68.00High
i
Rating by Derik De Bruin at Bank of America Co.
8/2/2018Craig HallumLower Price TargetBuy$60.00 ➝ $54.00High
i
7/23/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$67.00 ➝ $75.00Medium
i
7/18/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$67.00 ➝ $76.00Low
i
Rating by Puneet Souda at SVB Leerink LLC
7/9/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $70.00Low
i
6/18/2018CowenBoost Price TargetOutperform$65.00 ➝ $85.00Low
i
6/15/2018Canaccord GenuityBoost Price TargetBuy$70.00 ➝ $75.00Medium
i
6/6/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$68.00 ➝ $70.00Low
i
6/5/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $66.00Medium
i
6/5/2018BTIG ResearchReiterated RatingBuyMedium
i
5/31/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$60.00 ➝ $68.00Medium
i
5/30/2018BTIG ResearchBoost Price TargetPositive ➝ Buy$60.00 ➝ $70.00High
i
4/29/2018BTIG ResearchReiterated RatingBuy$60.00High
i
4/27/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$55.00 ➝ $60.00High
i
4/3/2018BTIG ResearchUpgradeNeutral ➝ BuyLow
i
3/29/2018William BlairReiterated RatingBuyN/A
i
Rating by Brian Weinstein at William Blair
3/28/2018SVB LeerinkSet Price TargetBuy$67.00High
i
Rating by Puneet Souda at SVB Leerink LLC
2/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$42.56 ➝ $56.00Medium
i
2/23/2018SVB LeerinkSet Price TargetBuy$67.00High
i
Rating by Puneet Souda at SVB Leerink LLC
2/23/2018BenchmarkDowngradeBuy ➝ HoldHigh
i
Rating by Raymond Myers at Benchmark Co.
2/9/2018SVB LeerinkSet Price TargetBuy$67.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.77 ➝ $51.00Low
i
1/17/2018BenchmarkSet Price TargetBuy$65.00Medium
i
Rating by Raymond Myers at Benchmark Co.
1/10/2018William BlairReiterated RatingBuyHigh
i
Rating by Brian Weinstein at William Blair
1/8/2018Bank of AmericaSet Price TargetBuy$67.00High
i
Rating by Derik De Bruin at Bank of America Co.
1/2/2018William BlairReiterated RatingBuyLow
i
Rating by Brian Weinstein at William Blair
11/29/2017Bank of AmericaBoost Price TargetBuy$58.00 ➝ $67.00Low
i
Rating by Derik De Bruin at Bank of America Co.
11/13/2017SVB LeerinkReiterated RatingOutperform$63.00 ➝ $67.00N/A
i
Rating by Puneet Souda at SVB Leerink LLC
11/13/2017Robert W. BairdDowngradeOutperform ➝ Neutral$56.00N/A
i
11/1/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
10/31/2017Bank of AmericaBoost Price TargetBuy$56.00 ➝ $58.00N/A
i
Rating by Derik De Bruin at Bank of America Co.
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/A
i
10/31/2017Robert W. BairdBoost Price TargetOutperform$49.00 ➝ $56.00N/A
i
10/31/2017Craig HallumBoost Price TargetBuy$46.00 ➝ $61.00N/A
i
10/31/2017BenchmarkReiterated RatingBuy ➝ Buy$50.00 ➝ $60.00N/A
i
Rating by Raymond Myers at Benchmark Co.
10/31/2017SVB LeerinkReiterated RatingOutperform$50.00 ➝ $63.00N/A
i
Rating by Puneet Souda at SVB Leerink LLC
10/31/2017Jefferies Financial GroupBoost Price TargetBuy$60.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/19/2017Bank of AmericaSet Price TargetBuy$40.00 ➝ $56.00N/A
i
Rating by Derik De Bruin at Bank of America Co.
10/6/2017Robert W. BairdReiterated RatingBuy$49.00N/A
i
10/3/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$45.00 ➝ $60.00High
i
9/21/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$45.00 ➝ $50.00High
i
Rating by Puneet Souda at SVB Leerink LLC
9/7/2017Canaccord GenuityReiterated RatingBuy$45.00Low
i
8/24/2017SVB LeerinkSet Price TargetBuy$45.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
7/26/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$42.00 ➝ $45.00High
i
7/26/2017Bank of AmericaReiterated RatingBuyHigh
i
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 ➝ $46.00High
i
Rating by C. Lewis at Roth Capital
7/26/2017Craig HallumReiterated RatingBuy$41.00 ➝ $46.00High
i
Rating by William Bonello at Craig Hallum
7/26/2017Lake Street CapitalBoost Price TargetHold ➝ Hold$30.00 ➝ $41.00Medium
i
7/20/2017Canaccord GenuityReiterated RatingBuy$38.00 ➝ $42.00Medium
i
Rating by Mark Massaro at Canaccord Genuity
7/17/2017BTIG ResearchReiterated RatingBuy$35.00 ➝ $45.00Low
i
7/7/2017BenchmarkSet Price TargetBuy$50.00Low
i
Rating by Raymond Myers at Benchmark Co.
7/7/2017Craig HallumBoost Price Target$35.00 ➝ $41.00High
i
Rating by William Bonello at Craig Hallum
6/12/2017Bank of AmericaReiterated RatingBuy$34.00 ➝ $38.00Low
i
6/9/2017Canaccord GenuityLower Price TargetBuy$40.00 ➝ $38.00Low
i
Rating by Mark Massaro at Canaccord Genuity
6/7/2017StephensSet Price TargetHold$28.00Medium
i
Rating by Drew Jones at Stephens
6/1/2017Roth CapitalReiterated RatingBuy$33.00 ➝ $40.00Low
i
Rating by C. Lewis at Roth Capital
6/1/2017Robert W. BairdReiterated RatingOutperform$40.00Low
i
Rating by Catherine W. Ramsey at Robert W. Baird
6/1/2017Jefferies Financial GroupSet Price TargetBuy$35.00Medium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/31/2017Canaccord GenuityBoost Price TargetBuy ➝ Buy$38.00 ➝ $40.00High
i
Rating by Mark Massaro at Canaccord Genuity
5/31/2017CowenReiterated RatingOutperform$45.00High
i
5/31/2017BenchmarkBoost Price TargetBuy ➝ Buy$34.00 ➝ $50.00High
i
5/16/2017Jefferies Financial GroupReiterated RatingBuy$35.00Low
i
5/15/2017CowenBoost Price TargetOutperform$40.00 ➝ $45.00N/A
i
5/5/2017CowenBoost Price TargetOutperform$40.00 ➝ $45.00Low
i
5/1/2017The Goldman Sachs GroupSet Price TargetNeutral$21.00 ➝ $33.00Medium
i
4/28/2017SVB LeerinkSet Price TargetBuy$38.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
4/27/2017CowenBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $40.00Low
i
4/26/2017Jefferies Financial GroupReiterated RatingBuy$25.00High
i
4/24/2017Canaccord GenuityReiterated RatingBuy$27.00Low
i
Rating by Mark Massaro at Canaccord Genuity
4/17/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$30.00Low
i
Rating by P. Souda at SVB Leerink LLC
4/4/2017CowenReiterated RatingOutperform$30.00Low
i
3/29/2017Bank of AmericaReiterated RatingBuyHigh
i
3/27/2017Craig HallumSet Price TargetBuy$28.00High
i
Rating by William Bonello at Craig Hallum
3/27/2017CowenInitiated CoverageOutperform$30.00High
i
2/22/2017Canaccord GenuityReiterated RatingBuy$27.00 ➝ $24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
2/22/2017Roth CapitalUpgradeNeutral ➝ Buy$15.00 ➝ $26.00N/A
i
Rating by C. Lewis at Roth Capital
2/21/2017BenchmarkUpgradeHold ➝ Buy$17.00 ➝ $27.00N/A
i
1/31/2017Craig HallumSet Price TargetBuy$26.00N/A
i
Rating by William Bonello at Craig Hallum
1/23/2017Canaccord GenuitySet Price TargetBuy$24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/9/2017Canaccord GenuitySet Price TargetBuy$24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/8/2017BTIG ResearchReiterated RatingBuy$22.00N/A
i
12/20/2016Robert W. BairdSet Price TargetBuy$22.00N/A
i
Rating by Catherine W. Ramsey at Robert W. Baird
12/13/2016Canaccord GenuitySet Price TargetBuy$24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
11/9/2016Canaccord GenuitySet Price TargetBuy$24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
11/1/2016Lake Street CapitalLower Price TargetHold$15.00 ➝ $8.00N/A
i
10/28/2016Canaccord GenuityReiterated RatingBuy$24.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
10/26/2016BenchmarkBoost Price TargetHold$14.00 ➝ $17.00N/A
i
10/4/2016Jefferies Financial GroupBoost Price TargetBuy$20.00 ➝ $23.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
9/4/2016Craig HallumSet Price TargetBuy$26.00N/A
i
Rating by william bonello at Craig Hallum
8/15/2016The Goldman Sachs GroupBoost Price TargetNeutral$16.00 ➝ $18.00N/A
i
8/1/2016Roth CapitalReiterated RatingHold$11.00 ➝ $15.00N/A
i
Rating by Chris Lewis at Roth Capital
7/31/2016Robert W. BairdReiterated RatingOutperform$18.00N/A
i
7/31/2016BTIG ResearchReiterated RatingBuy$20.00N/A
i
Rating by Sean Lavin at BTIG Research
7/27/2016Craig HallumBoost Price TargetBuy$18.00 ➝ $26.00N/A
i
Rating by William Bonello at Craig Hallum
7/27/2016Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
7/27/2016BenchmarkLower Price TargetHold$14.00 ➝ $9.00N/A
i
Rating by Jan Wald at Benchmark Co.
7/27/2016MizuhoBoost Price TargetNeutral$10.00 ➝ $15.00N/A
i
Rating by Eric Criscuolo at Mizuho
7/26/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Mark Massaro at Canaccord Genuity
7/15/2016William BlairReiterated RatingOutperform$29.00N/A
i
Rating by Brian Weinstein at William Blair
6/22/2016Craig HallumReiterated RatingBuyN/A
i
Rating by William Bonello at Craig Hallum
6/22/2016Robert W. BairdReiterated RatingOutperform$12.00 ➝ $15.00N/A
i
6/16/2016Craig HallumUpgradeHold ➝ Buy$6.00 ➝ $18.00N/A
i
Rating by William Bonello at Craig Hallum
6/15/2016William BlairReiterated RatingBuyN/A
i
Rating by Brian Weinstein at William Blair
6/15/2016Roth CapitalReiterated RatingHold$7.00 ➝ $7.00N/A
i
Rating by Chris Lewis at Roth Capital
6/15/2016Jefferies Financial GroupReiterated RatingBuy$13.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
6/15/2016Canaccord GenuityReiterated RatingBuy$9.00 ➝ $12.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
6/15/2016MizuhoReiterated RatingHold$6.50N/A
i
Rating by Eric Criscuolo at Mizuho
6/15/2016BTIG ResearchReiterated RatingBuy$9.00N/A
i
Rating by Sean Lavin at BTIG Research
5/24/2016BTIG ResearchReiterated RatingBuy$9.00N/A
i
Rating by Sean Lavin at BTIG Research
5/10/2016BTIG ResearchReiterated RatingBuyN/A
i
Rating by Sean Lavin at BTIG Research
5/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
5/4/2016MizuhoDowngradeBuy ➝ Neutral$12.00 ➝ $6.50N/A
i
5/2/2016Canaccord GenuityReiterated RatingBuy$9.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
3/1/2016BTIG ResearchReiterated RatingBuy$9.00N/A
i
Rating by Sean Lavin at BTIG Research
2/26/2016The Goldman Sachs GroupLower Price TargetNeutral$8.00 ➝ $7.00N/A
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
2/25/2016Canaccord GenuityLower Price TargetBuy$13.00 ➝ $9.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
2/25/2016StephensDowngradeOverweight ➝ Equal WeightN/A
i
Rating by Drew Jones at Stephens
2/25/2016Jefferies Financial GroupLower Price TargetBuy$15.00 ➝ $13.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
2/25/2016Roth CapitalDowngradeBuy ➝ NeutralN/A
i
Rating by Chris Lewis at Roth Capital
2/24/2016BenchmarkReiterated RatingHold$11.00 ➝ $9.00N/A
i
Rating by Jan Wald at Benchmark Co.
2/24/2016Craig HallumDowngradeBuy ➝ Hold$22.00 ➝ $6.00N/A
i
Rating by William Bonello at Craig Hallum
(Data available from 2/24/2016 forward)
Exact Sciences logo
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $134.82
$133.54
$140.69

50 Day Range

MA: $143.99
$124.28
$155.01

52 Week Range

Now: $134.82
$35.25
$159.54

Volume

1,847,669 shs

Average Volume

1,925,685 shs

Market Capitalization

$22.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Bank of America Co., Benchmark Co., BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Craig Hallum, Evercore ISI, Oppenheimer Holdings Inc., Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

16 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $145.31, suggesting a possible upside of 4.8%. Truist has the highest price target set, predicting EXAS will reach $226.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $70.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 3 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is 608-535-8815 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com.